HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING—
Price Investing Group
← Back to Research Watchlist
CYTK
Cytokinetics Inc
Healthcare Biotechnology · California, USA · Reports in usd
—
Market Cap: $7.83B
Market Cap
$7.83B
Enterprise Val
$7.93B
P/E Ratio
-8.76
P/B Ratio
-45.12
Trailing PEG (1Y)
-0.26
As Of
Oct 8, 2026

Overview & Key Metrics

Reporting period: Jun 30, 2026 · Q2 2026
Book Value-$173.5M
Gross Margin80.46%
Profit Margin80.46%
Return on Equity163.98%
Return on Assets-59.02%
Current Ratio6.66
Debt/Equity-7.32
LT Debt/Equity-7.04
Revenue Per Share0.23

Income Statement

Jun 30, 2026
Revenue$28.6M
Cost of Revenue$5.6M
Gross Profit$23.0M
R&D$97.8M
SG&A$104.4M
Operating Expenses$202.2M
Operating Income-$179.2M
Interest Expense$14.7M
Tax Expense$0.00
Net Income-$198.8M
EPS (Basic)$-1.50
EPS (Diluted)$-1.50
EBIT-$184.1M
EBITDA-$180.5M
Consolidated Income-$198.8M
Non-Controlling Interests$0.00

Balance Sheet

Jun 30, 2026
Cash & Equivalents$255.3M
Accounts Receivable$24.4M
Inventory$6.9M
Current Assets$1.21B
LT Investments$538.3M
Property, Plant & Equipment$151.8M
Intangibles$0.00
Non-Current Assets$716.1M
Total Assets$1.92B
Accounts Payable$20.5M
Current Debt$48.4M
Current Liabilities$181.4M
LT Debt$1.22B
Non-Current Liabilities$1.92B
Total Liabilities$2.10B
Total Debt$1.27B
Retained Earnings-$3.89B
Shareholder Equity-$173.5M
Shares Outstanding124,432,565

Cash Flow Statement

Jun 30, 2026
Operating Cash Flow-$159.8M
Investing Cash Flow-$507.0M
Financing Cash Flow$792.9M
CapEx-$4.3M
Free Cash Flow-$164.2M
Depreciation & Amort.$3.6M
Stock-Based Comp$35.7M
Acquisitions / Disposals$0.00
Investment Activity-$502.7M
Debt Issued/Repaid-$3.8M
Equity Issued/Repaid$798.2M
Dividends Paid$0.00
Net Change in Cash$125.4M
Data cached · Meta live · Daily live · Statements live · TTL 24h